Top Injectable Manufacturer in Niger – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 1 day ago
- 14 min read
Last Updated: July 25, 2026
TL;DR: Niger is a Sahelian market of roughly 28 million people with one of the heaviest injectable-medicine burdens in the world and almost no domestic capacity to fill it. It is a WHO High Burden to High Impact malaria country — an estimated 7,982,516 cases and 35,381 deaths in 2023, about 3% of global malaria cases and 5.9% of global malaria deaths — and its own national guidelines make intravenous artesunate or artemether the first-line treatment for severe malaria in every trimester of pregnancy. Niger also sits inside the African meningitis belt, recorded 1,926 suspected diphtheria cases and 122 deaths between January and November 2025, and carries the highest neonatal, 1–59-month and under-five mortality rates in the whole of West and Central Africa. Market access has changed materially: since 2022 the regulator is the Agence Nigérienne de Réglementation du secteur Pharmaceutique (ANRP), not the old Direction de la Pharmacie, and the Autorisation de Mise sur le Marché is now signed by the ANRP Director-General on a CTD dossier built to UEMOA Règlement n°04/2020/CM/UEMOA. Niger left ECOWAS on 29 January 2025 but remains in UEMOA, so that CTD framework still governs. Importation is reserved by law to a licensed établissement managed by a pharmacist of Nigerien nationality, every consignment needs a ministerial visa plus an import authorisation, and because Niger is not a party to the Hague Apostille Convention the CPP and GMP certificate require full consular legalisation — not the apostille that works for neighbouring Nigeria. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to over 30 countries, and supports Nigerien partners with French CTD dossiers, consular-legalised documentation and Zone IVb stability packages.
Key Takeaways
The regulator changed in 2022 — get the name right. Niger's medicines regulatory authority is the Agence Nigérienne de Réglementation du secteur Pharmaceutique (ANRP), created by Décret n°2022-539/PRN/MSP/P/AS of 29 June 2022 as an autonomous public establishment under the Ministère de la Santé et de l'Hygiène Publique, with its head office in Niamey. It absorbed the regulatory functions historically exercised by the Direction de la Pharmacie et de la Médecine Traditionnelle. Under UEMOA Règlement n°04/2020/CM/UEMOA of 28 September 2020, the Autorisation de Mise sur le Marché is now issued by the ANRP Director-General rather than the Minister of Health, on a CTD dossier — four modules for generics, five for reference products — with Module 1 in French, 50 samples for a generic application, a final binding technical opinion from the Commission Nationale du Médicament, five years' validity, renewal filed 120 days before expiry, and a 120-day standard assessment inside a 360-day outer limit.
The ECOWAS exit did not dismantle the registration framework — because Niger stayed in UEMOA. Niger's withdrawal from ECOWAS took effect on 29 January 2025 alongside Mali and Burkina Faso, and the three are founding members of the Alliance des États du Sahel (AES). But Niger remains a UEMOA member and continues to use the CFA franc, so UEMOA Règlement 04/2020 — which was itself written to let member states use the ECOWAS-harmonised CTD format — still applies directly. The AMM remains purely national: there is no community-wide authorisation and no EU-style mutual recognition, so a product must be registered in Niger for Niger. Note also the AES Confederal Levy of 0.5% on imports from outside the bloc, adopted on 28 March 2025, which removed the duty advantage ECOWAS-origin competitors previously enjoyed.
You cannot import in your own name, and each shipment is individually controlled. Under Ordonnance n°97-002 of 10 January 1997, still in force, an importation and wholesale distribution establishment must be owned by pharmacists or be a company whose management is provided by a pharmacist of Nigerien nationality (Art. 84), licensed by the Minister of Health after the opinion of the Conseil National de l'Ordre (Art. 83). Before any customs release the importer must hold a ministerial visa (Art. 87), and every single importation additionally requires a ministerial authorisation plus certificates of analysis from a State-approved quality-control laboratory (Art. 88). Public-sector volume flows mainly through ONPPC, the Office National des Produits Pharmaceutiques et Chimiques, restructured by Ordonnance n°99-046 of 26 October 1999.
Documentation runs on consular legalisation, and this is where the Niger–Nigeria trap catches exporters. Niger is not a Contracting Party to the 1961 Hague Apostille Convention — a check of the HCCH status table confirms no entry for Niger, consistent with Mali and Burkina Faso. Nigeria, a different country, did accede, and several commercial apostille services wrongly list Niger as a member on that basis. For Niger the Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale must travel the full consular chain, and Module 1 must be in French. On stability, no ANRP, UEMOA or WHO document formally assigns Niger a climatic zone; Farbe Firma files long-term data at 30°C/75% RH, which satisfies Zone III, IVa and IVb simultaneously and removes the risk of a deficiency letter.
Introduction: Why an Injectable Manufacturer in Niger Must Meet Global Standards
Niger's health system serves roughly 28 million people through a three-tier pyramide sanitaire: national hospitals and specialist centres in Niamey at the apex, Centres Hospitaliers Régionaux and referral maternities across the eight regional health directorates in the middle, and at the operational base the district hospitals with their networks of Centres de Santé Intégrés and community health huts. The scale of that base is genuinely large — reported figures include around 883 CSIs of which 881 are functional, some 2,501 health huts, and 33 district hospitals of which 27 have functional operating theatres, spread across 72 health districts, with 135 new CSIs constructed in 2024 alone extending access to a further 320,000 people. Public-sector essential medicines are supplied through ONPPC, the Office National des Produits Pharmaceutiques et Chimiques, which operates three zonal warehouses feeding district depots and regional hospitals under both pull and push distribution, with a dedicated management unit handling donor-funded commodities for malaria, tuberculosis, HIV and family planning. For a sterile injectable supplier the practical consequence is that a single national registration opens several distinct doors — ONPPC procurement, donor-funded programme supply through the Global Fund, UNICEF, Gavi and UNFPA channels, regional and district hospital purchasing, and the private wholesale and retail trade — each with its own qualification rhythm.
The demand behind that structure is severe. Malaria is endemic nationwide and Niger is one of the countries designated under the WHO High Burden to High Impact approach: the World Malaria Report 2024 put 2023 at an estimated 7,982,516 cases and 35,381 deaths, roughly 3% of all global malaria cases and 5.9% of global malaria deaths, with incidence rising from 295 to 305 per 1,000 population at risk. The World Malaria Report 2025 placed Niger at 6.1% of all malaria deaths in the WHO African Region and named it one of only four countries accounting for more than half of global malaria deaths. Niger's own national guidelines make intravenous artesunate or artemether the strongly recommended treatment for severe malaria, with quinine as the alternative and intravenous artesunate indicated in all trimesters of pregnancy — a direct, guideline-level demand signal for parenteral antimalarials. Layered on top: a position inside the African meningitis belt, where the 2024 outbreak affected more than 2,600 people and Niger became one of the first two countries anywhere to deploy the pentavalent Men5CV vaccine in outbreak response; 1,926 suspected diphtheria cases and 122 deaths between 1 January and 2 November 2025, a case fatality rate of 6.3%; a maternal mortality ratio of about 350 per 100,000 live births; an under-five mortality rate of 114.8 per 1,000 with 119,782 under-five deaths in 2023, the highest neonatal, 1–59-month and under-five rates in West and Central Africa; and chronic malnutrition affecting 45.7% of under-fives. Against that, Niger remains heavily import-dependent — pharmaceutical imports alone reached CFA 66.9 billion in the fourth quarter of 2025 — while regional production covers barely 10% of West African needs.
What Sets a World-Class Injectable Manufacturer in Niger Apart
The first differentiator is genuine sterile-manufacturing capability rather than a general plant with a filling line bolted on. Sterile injectables bypass every natural barrier the body has, so sterility assurance cannot be inferred from a finished-product test alone — it has to be designed into the facility. Farbe Firma's operation in Gujarat, India is built around ISO Class 5 aseptic filling zones within classified surrounding areas, unidirectional personnel and material flows, validated terminal sterilisation or aseptic processing according to the molecule, routine media-fill validation, environmental and personnel monitoring with trended data, and Water-for-Injection generation and distribution held under continuous control. That architecture is what turns a certificate of analysis into a defensible claim. In Niger it matters twice over, because the country enforces quality on arrival as well as on paper: the Ministry of Health requires that antimalarials delivered into Niger hold a Nigerien marketing authorisation, comply with WHO standards, and be tested for quality on arrival and again six months later, while the national quality-control laboratory LANSPEX operates to ISO/IEC 17025:2017 under a formal 2025 convention with the ANRP.
The second differentiator is market-access support built around Niger's actual pathway, including the parts that are inconvenient. The authorisation is the Autorisation de Mise sur le Marché, and since UEMOA Règlement n°04/2020/CM/UEMOA it is signed by the ANRP Director-General on a CTD dossier assessed in three stages — administrative review by the ANRP, technical evaluation by a committee of experts, and a final binding technical opinion from the Commission Nationale du Médicament. Generics file four CTD modules with 50 samples and batch certificates of analysis; Module 1 must be in French, and the SmPC, leaflet and labelling must be consistent and in an official language. Validity is five years, renewal must be filed 120 days before expiry, and the 2020 regulation reclassified 22 formerly minor variations as major — covering active-substance manufacturing process, batch size, specification tightening, test methods, new or changed manufacturing sites, primary packaging composition and in-process controls — each triggering a full dossier re-evaluation. A useful supplier plans for that. It also plans for the parts a manufacturer cannot do alone: an Indian manufacturer cannot import in its own name, because importation and wholesale are reserved to a licensed établissement owned by pharmacists or managed by a pharmacist of Nigerien nationality, and every consignment needs a ministerial visa before customs release plus a separate per-importation authorisation and certificates of analysis from a State-approved laboratory.
Quality Systems Behind Every Batch We Ship to Niger
Every Farbe Firma injectable batch destined for Niger is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by HPLC and, where the monograph requires it, GC. Sterility and bacterial endotoxin testing by LAL are performed on every batch, with container-closure integrity and particulate matter assessed against compendial limits, and water content by Karl Fischer titration where the dosage form demands it. Methods are validated to ICH expectations and specifications are set against USP, BP, IP or EP as the market and customer require, with the pharmacopoeial basis stated on the certificate of analysis rather than left implicit. That discipline is not decorative in Niger: because each importation must be accompanied by certificates of analysis from a State-approved quality-control laboratory, and because antimalarials are retested on arrival and at six months, a batch record that cannot be defended line by line becomes a customs problem rather than a quality-department problem.
Behind release testing sits the quality architecture that makes those results meaningful. Stability programmes run on three batches under real-time conditions per ICH Q1A, with photostability per ICH Q1B where the molecule warrants it. On climatic zone we are deliberately careful, because no ANRP, UEMOA or WHO document formally assigns Niger a zone: meteorologically Sahelian Niger is hot and dry, which on climate alone maps to Zone III at 30°C/35% RH, but ICH Q1F harmonised Zones III and IV at 30°C/65% RH before being withdrawn in 2006, leaving the definition to WHO and the regions. We therefore file long-term data at 30°C ± 2°C / 75% RH ± 5% with accelerated testing at 40°C ± 2°C / 75% RH ± 5% — a condition explicitly listed as acceptable in WHO Technical Report Series No. 1010, Annex 10, which simultaneously satisfies Zone III, IVa and IVb, covers the humid coastal UEMOA markets a Nigerien registration is often extended into, and eliminates the risk of a stability deficiency letter. Change control, deviation management, CAPA, supplier qualification and annual product quality review operate as a connected system rather than as separate files, batch records are retained so that any vial can be reconstructed from raw material to release years later, French dossiers and artwork are prepared to the regulator's requirements, and the site is maintained in a state of continuous inspection readiness.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Niger for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, oncology support, anaesthesia and analgesia, cardiovascular and critical-care molecules, obstetric medicines, vitamins and parenteral-nutrition adjuncts, delivered as liquid vials, ampoules, lyophilised presentations and small-volume parenterals — which maps closely onto what Niger's epidemiology actually consumes. Injectable artesunate and injectable artemether sit at the top of the national severe-malaria guideline with quinine as the named alternative; oxytocin, magnesium sulphate and tranexamic acid answer a maternal mortality ratio near 350 per 100,000; injectable antibiotics answer neonatal and maternal sepsis, pneumonia treated through integrated community case management, the meningitis-belt caseload and a diphtheria outbreak that ran to 1,926 suspected cases and 122 deaths in 2025. For a Nigerien établissement assembling a hospital portfolio, or a distributor qualifying for ONPPC and donor-funded tenders, that breadth means one audited manufacturing partner, one documentation standard and one point of accountability rather than a patchwork of sources with uneven paperwork.
Our CDMO services scale from a single distributor's launch portfolio to full tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, analytical method transfer, stability commitment and regulatory documentation handled as one package. We prepare the CTD dossier for the AMM in the UEMOA Règlement 04/2020 structure with Module 1 in French, provide the WHO-format Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale legalised through the full consular chain, prepare French labelling, SmPC and inserts consistent with the authorisation, and supply the batch-level certificates of analysis and retention-sample discipline that an importer's responsible pharmacist needs in order to defend a product line — and that Niger's per-consignment rules make non-negotiable. We also handle the variation load honestly at the outset, because under the 2020 regulation a change of manufacturing site, primary packaging composition or in-process control is now a major variation requiring full re-evaluation, and that shapes how a portfolio should be structured before the first filing rather than after it.
Buyers stay with Farbe Firma because we are straightforward about what the Nigerien route actually involves. Registration and importation must run through a locally licensed établissement owned by pharmacists or managed by a pharmacist of Nigerien nationality — a manufacturer cannot file or import in its own name — and each shipment needs its own ministerial visa, import authorisation and State-laboratory certificates of analysis. Because Niger is outside the Hague Apostille Convention, every certificate must be consular-legalised rather than apostilled: this is the single most common error we see, and it usually stems from confusing Niger with Nigeria, which did accede to the Convention. We are equally candid that the ANRP is a young institution whose published procedures, fee schedules and application forms are not yet available online, so realistic timelines and direct engagement with Niamey matter more here than in a market with a mature public portal; and that the Sahel has a serious substandard-and-falsified-medicines problem, with UNODC finding between 19% and 50% of medicines in Sahel markets substandard or falsified and about 40% of the substandard and falsified products reported across 2013–2021 discovered inside the regulated supply chain rather than only in informal markets. Niger has responded by ratifying the MEDICRIME Convention and, in October 2023, withdrawing 25 pharmaceutical products from the market. That environment rewards a WHO-GMP supplier competing on verifiable quality and documentation rather than on price alone, and we would rather set out the local-partner requirement, the legalisation chain and the French-language obligations at the first meeting than discover the gap at the point of filing.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Niger?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable products under ISO Class 5 aseptic conditions and exporting to over 30 countries. For Niger we prepare the CTD dossier in the UEMOA Règlement n°04/2020/CM/UEMOA structure with Module 1 in French, provide a WHO-format Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale legalised through the full consular chain, prepare French labelling, SmPC and package inserts, and hold long-term stability data at 30°C/75% RH. Because importation and wholesale distribution are reserved by law to a licensed établissement owned by pharmacists or managed by a pharmacist of Nigerien nationality, we work alongside a client's local importer rather than filing or importing in our own name.
How is an imported injectable registered in Niger, and who issues the authorisation?
The authorisation is the Autorisation de Mise sur le Marché (AMM). Since 2022 the competent authority is the Agence Nigérienne de Réglementation du secteur Pharmaceutique (ANRP), created by Décret n°2022-539/PRN/MSP/P/AS of 29 June 2022 under the Ministère de la Santé et de l'Hygiène Publique, and under UEMOA Règlement n°04/2020/CM/UEMOA the AMM is signed by the ANRP Director-General rather than the Minister of Health. The dossier is filed in CTD format — four modules for generics, five for reference products and vaccines — with Module 1 in French, 50 samples and batch certificates of analysis, and is assessed in three stages: administrative review by the ANRP, technical evaluation by a committee of experts, and a final binding technical opinion from the Commission Nationale du Médicament. Validity is five years, standard assessment is 120 days within a 360-day outer limit, and renewal must be filed 120 days before expiry. The AMM is purely national — there is no UEMOA-wide authorisation — so the product must be registered in Niger specifically. Note that Niger's own Ordonnance 97-002 of 1997 still names the Minister of Health as the issuing authority; the 2020 regional regulation governs in practice, but the national text has not visibly been updated.
Does Niger accept an apostille, or is consular legalisation required?
Consular legalisation is required. Niger is not a Contracting Party to the Hague Convention of 5 October 1961 Abolishing the Requirement of Legalisation for Foreign Public Documents, so a certificate carrying only an apostille is not sufficient. Be careful here: this is one of the most frequent and most expensive mistakes in West African market entry, because Nigeria — an entirely different country — did accede to the Apostille Convention, and several commercial apostille services wrongly list Niger as a member on that basis. For Niger the Certificate of Pharmaceutical Product, GMP certificate, Certificate of Free Sale, manufacturing licence and power of attorney to the local agent must travel the full consular chain from the country of origin. Farbe Firma plans that chain into the registration timeline from the outset, and prepares Module 1, labelling and inserts in French.
Did Niger's exit from ECOWAS change how injectables are registered there?
Not in the way most people assume. Niger's withdrawal from ECOWAS took effect on 29 January 2025, alongside Mali and Burkina Faso, and the three countries are founding members of the Alliance des États du Sahel. However Niger remains a member of UEMOA and continues to use the CFA franc, and it is UEMOA Règlement n°04/2020/CM/UEMOA that governs registration — a regulation that was itself drafted to let UEMOA member states use the ECOWAS-harmonised CTD format. So the CTD framework, the five-year AMM, the 120-day assessment and the ANRP's role all survive the exit. What is genuinely unclear is whether Niger continues to participate in the ECOWAS-level West African Medicines Regulatory Harmonization joint-assessment programme run through WAHO; no public source confirms this either way. On the trade side, the AES adopted a 0.5% Confederal Levy on 28 March 2025 covering imports from outside the bloc, including from ECOWAS states, which removed the duty advantage ECOWAS-origin manufacturers previously held into Niger.
How does public procurement for injectables work in Niger, and is there local competition?
The principal public channel is ONPPC, the Office National des Produits Pharmaceutiques et Chimiques, restructured by Ordonnance n°99-046 of 26 October 1999 into a public industrial and commercial enterprise with wholesaler-distributor-retailer status. ONPPC supplies essential medicines and consumables through three zonal warehouses to district depots and regional hospitals, operating both pull and push distribution, with a dedicated unit handling donor-funded commodities for malaria, tuberculosis, HIV and family planning; care and products are free at the point of use for children under five and pregnant women. Alongside ONPPC sit substantial donor-funded channels — the Global Fund, UNICEF, Gavi, UNFPA and, historically, PMI/USAID — plus private purchasing centres and licensed wholesalers. A valid AMM and presence on the Liste Nationale des Médicaments Essentiels are the practical preconditions for public supply. On local competition, Niger's state manufacturer NIPHAR replaced SONIPHAR in February 2025, and the Minister of Health confirmed in April 2026 that paracetamol, some antibiotics such as cotrimoxazole and sérums — infusion solutions — are made locally; we have found no evidence of domestic small-volume sterile injectable capacity in ampoules or vials, or of a WHO-GMP certified sterile line, so large-volume parenterals are the one sterile category where a local alternative already exists.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments